EUVIMEDEUVIMED entdecken
Crossref

The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population

Wenxin Xu, Yaru Shi, Zhihong Liu, Hong Ma, Junqi Niu, Qing Xie iD, Jianping Xie, Huiying Rao iD, Song Yang iD, Chunxiu Zhong, Xiaoguang Dou iD, Dongying Xie und 15 weitere

Liver International · 2026-11 · 46 (11)

DOI: 10.1111/liv.70936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 21.10.2026. Verfasst von Wenxin Xu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Liver. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Steatotic liver disease (SLD) is an increasingly important cause of hepatocellular carcinoma (HCC), yet validated risk stratification tools remain limited. We aim to evaluate the aMAP score, initially developed for HCC risk prediction mainly in viral hepatitis across international cohorts, in the SLD population.

Methods

156 406 SLD participants were included from the UK Biobank (UKB) and 3166 SLD patients with virally suppressed chronic hepatitis B from a Chinese cohort. The predictive and stratification performance of the aMAP score was assessed and compared with the PAGE‐B, mPAGE‐B, CAMD and MASLD‐HCC scores. A refined stratification of the aMAP‐defined high‐risk population identified a subgroup exceeding the recommended surveillance threshold.

Results

Median follow‐up was 13.64 years in UKB and 9.97 years in the Chinese cohort, with 287 and 58 patients developing HCC, respectively. The aMAP score showed favourable discrimination (C‐indices: 0.80 [95% CI, 0.78–0.83] in UKB; 0.79 [95% CI, 0.73–0.85] in the Chinese cohort). The 15‐year cumulative HCC incidence by aMAP in UKB was 0.06% (95% CI, 0.04%–0.08%), 0.26% (95% CI, 0.21%–0.31%) and 1.43% (95% CI, 1.14%–1.72%) for low‐, intermediate‐ and high‐risk groups (high vs. low risk, sHR: 28.51; 95% CI, 19.58–41.52; Gray's test p < 0.001). Consistent results were found across etiological subgroups and in the other cohort (Gray's test p < 0.001). The refined cutoff (aMAP > 64) identified a very‐high‐risk subgroup in UKB with 15‐year cumulative incidences of 3.08% (training; 95% CI, 1.29%–4.87%) and 5.35% (validation; 95% CI, 3.04%–7.67%).

Conclusions

The aMAP score is an effective tool for HCC risk stratification among SLD patients. The refined aMAP threshold accurately identifies very‐high‐risk patients qualifying for guideline‐recommended surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsFatty LiverHumansFemaleRisk AssessmentMiddle AgedMaleRisk FactorsHepatitis B, ChronicChinaUnited KingdomAdultAgedIncidence

Stichwörter der Autor:innen

fatty liverhepatocellular cancerrisk assessment

Autor:innen und Institutionen

  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangzhou, China.
  • Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangzhou, China.
  • Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangzhou, China.
  • Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Hepatology, First Hospital, University of Jilin, Changchun, China.

ORCID-Profile: Qing Xie, Huiying Rao, Song Yang, Xiaoguang Dou, Yongfeng Yang, Qiang Li, Hong Tang, Jianqi Lian, Jinlin Hou, Rong Fan

Förderung

  • National Science and Technology Major Project

Zitieren

APA

Xu, W., Shi, Y., Liu, Z., Ma, H., Niu, J., Xie, Q., Xie, J., Rao, H., Yang, S., Zhong, C., Dou, X., Xie, D., Yin, J., Sun, A., Yang, Y., Liu, Y., Xu, Y., Li, Q., Jiang, Y., …, & Chronic Hepatitis B Study Consortium (2026). The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population. Liver International, 46(11). https://doi.org/10.1111/liv.70936

Vancouver

Xu W, Shi Y, Liu Z, Ma H, Niu J, Xie Q, et al. The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population. Liver International. 2026;46(11). doi:10.1111/liv.70936

BibTeX
@article{Xu2026,
  author = {Xu, Wenxin and Shi, Yaru and Liu, Zhihong and Ma, Hong and Niu, Junqi and Xie, Qing and Xie, Jianping and Rao, Huiying and Yang, Song and Zhong, Chunxiu and Dou, Xiaoguang and Xie, Dongying and Yin, Junhua and Sun, Aimin and Yang, Yongfeng and Liu, Yali and Xu, Ya and Li, Qiang and Jiang, Yongfang and Li, Wu and Tang, Hong and Lian, Jianqi and Lin, Huapeng and Sun, Jian and Hou, Jinlin and Fan, Rong and Chronic Hepatitis B Study Consortium, Chronic Hepatitis B Study Consortium},
  title = {The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {11},
  doi = {10.1111/liv.70936}
}
Kostenlos starten →